Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Qingdao Huanghai Biological Pharmaceutical Sets Up Sodium Alginate Production Base

This article was originally published in PharmAsia News

Executive Summary

Qingdao Huanghai Biological Pharmaceutical, a subsidiary of Qingdao Huanghai Pharmaceutical, recently hosted a ground-breaking ceremony for its medical sodium alginate production project in Jiaozhou city, Qingdao. With a total investment of RMB 300 million, the 66,072-square-meter facility began construction in February and is scheduled for operation at year end. The first phase, with RMB 100 million funding, will involve setting up a raw pharmaceutical materials production workshop, office buildings, warehouses and auxiliary facilities. Huanghai Biological will mainly produce azelnidipine and sodium alginate, and target a production value of RMB 1 billion for sodium alginate within three years. Analysts see the move significant since the plant represents China's first sodium alginate manufacturing facility for medical use, indicating the market potential for local biopharmaceutical industry development. (Click here for more - Chinese Language)

You may also be interested in...

Sun's Halol Site Faces FDA Action

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.

Dr Reddy’s And Hikma Win Big On US Vascepa Patents

In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.

Manipulating Metabolism: Lilly Links With UK Biotech Sitryx

Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts